Aligos Therapeutics, Inc. (ALGS) stock
ALGSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/3053% below fair value
$1.30−0.06 (-4.41%)
Close on Nov 18, 2026Market cap $16.24MP/E –Yield –
Aligos Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Aligos Therapeutics's free cash flow for the twelve months ending Mar 31, 2023 was -$81.78M. For fiscal 2024 it was -$80.87M. The highest annual figure on record is -$49.55M in fiscal 2019.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$80.87M | – |
| FY2023 | Dec 31, 2023 | -$79.02M | – |
| FY2022 | Dec 31, 2022 | -$80.33M | – |
| FY2021 | Dec 31, 2021 | -$116.55M | – |
| FY2020 | Dec 31, 2020 | -$76.33M | – |
| FY2019 | Dec 31, 2019 | -$49.55M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2023 | Mar 31, 2023 | -$22.39M | – |
| Q4 FY2022 | Dec 31, 2022 | -$16.87M | – |
| Q3 FY2022 | Sep 30, 2022 | -$17.14M | – |
| Q2 FY2022 | Jun 30, 2022 | -$25.37M | – |
| Q1 FY2022 | Mar 31, 2022 | -$20.95M | – |
| Q4 FY2021 | Dec 31, 2021 | -$37.82M | – |
| Q3 FY2021 | Sep 30, 2021 | -$25.47M | – |
| Q2 FY2021 | Jun 30, 2021 | -$23.17M | – |
| Q1 FY2021 | Mar 31, 2021 | -$30.10M | – |
| Q4 FY2020 | Dec 31, 2020 | -$19.75M | – |
| Q3 FY2020 | Sep 30, 2020 | -$16.91M | – |
| Q2 FY2020 | Jun 30, 2020 | -$18.26M | – |
| Q1 FY2020 | Mar 31, 2020 | -$21.41M | – |
| Q4 FY2019 | Dec 31, 2019 | -$15.74M | – |
See a number that looks wrong?